ICVAX / Immuno Cure - LARVOL DELTA

Safety and Immunogenicity of a PD-1-Enhanced HIV-1 Therapeutic DNA Vaccine: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Phase I Clinical Trial in People With HIV-1 on Antiretroviral Therapy. (PubMed, J Infect Dis) - P1 | "ICVAX was well-tolerated and elicited robust antigen-specific T-cell responses in ART-suppressed people with HIV-1. Its efficacy will be assessed in future studies."

Clinical • First-in-human • Journal • P1 data • Human Immunodeficiency Virus • Infectious Disease • LAMP1

HIV Therapeutic DNA Vaccine (ICVAX) Phase I Clinical Trial in Hong Kong (clinicaltrials.gov) - P1 | N=22 | Recruiting | Sponsor: Immuno Cure Holding (HK) Limited

New P1 trial • Human Immunodeficiency Virus • Infectious Disease • CD4

YKYY-ICVAX-101: ICVAX as a HIV Therapeutic DNA Vaccine (clinicaltrials.gov) - P1 | N=45 | Completed | Sponsor: Immuno Cure Holding (HK) Limited | Active, not recruiting ➔ Completed

Trial completion • Human Immunodeficiency Virus • Infectious Disease • CD4

YKYY-ICVAX-101: ICVAX as a HIV Therapeutic DNA Vaccine (clinicaltrials.gov) - P1 | N=45 | Active, not recruiting | Sponsor: Immuno Cure Holding (HK) Limited | Trial completion date: Jan 2025 ➔ Jun 2025

Trial completion date • Human Immunodeficiency Virus • Infectious Disease

YKYY-ICVAX-101: ICVAX As a HIV Therapeutic DNA Vaccine (clinicaltrials.gov) - P1 | N=45 | Active, not recruiting | Sponsor: Immuno Cure Holding (HK) Limited | Trial primary completion date: Jun 2024 ➔ Sep 2024

Trial primary completion date • Human Immunodeficiency Virus • Infectious Disease

A novel PD1-enhanced DNA vaccine in PLWH under cART: a Phase 1, randomized, double-blinded, placebo-controlled, and dose-escalation study (AIDS 2024) - "These data suggest that ICVAX in ART-suppressed PLWH is safe and immunogenic and that larger clinical trials are needed to further investigate the effects of ICVAX on reservoirs."

Clinical • P1 data • Human Immunodeficiency Virus • Infectious Disease • Pain • CD4 • PD-1

ICVAX as a HIV Therapeutic DNA Vaccine (clinicaltrials.gov) - P1 | N=45 | Active, not recruiting | Sponsor: Shenzhen Immuno Cure Biomedical Company Limited

New P1 trial • Human Immunodeficiency Virus • Infectious Disease